<DOC>
	<DOCNO>NCT02923115</DOCNO>
	<brief_summary>This Phase 1b , double-blind ( Principal Investigators , study subject , Sponsor , Academic Research Organization ARO Clinical Research Organization CRO blind ) , placebo-controlled , randomize , single-ascending dose , multi-center study ass safety , efficacy , tolerability , pharmacokinetics PK , pharmacodynamics PD DS-1040b subject acute submassive pulmonary embolism .</brief_summary>
	<brief_title>Randomized Study Assess Safety , Pharmacokinetics/Dynamics DS-1040b Subjects With Acute Submassive Pulmonary Embolism</brief_title>
	<detailed_description />
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Pulmonary Embolism</mesh_term>
	<criteria>Male female subject , age 18 75 year admit hospital clinical diagnosis acute PE categorize low risk intermediaterisk submassive PE catheterbased therapy plan ; Subjects must CTA scan confirm PE diagnosis least one measurable index lesion segmental large pulmonary artery prior randomization ; Subjects otherwise satisfactory health opinion Investigator ; Subjects must able provide write informed consent . Subjects acute PE categorize highrisk massive , hemodynamically unstable , evidenced heart rate &gt; 120 /min systolic blood pressure ( SBP ) &lt; 90 mmHg 15 consecutive minute drop SBP &gt; 40 mmHg since presentation ; Subjects use thrombolytic , either systemic via catheter , plan ; Subjects PE lesion subsegmental small artery ; Subjects receive vitamin K antagonist ( VKAs ) prior randomization receive 36 hour treatment LMW ( low molecular weight Heparin ) therapeutic dos prior randomization ; Subjects prior intracranial hemorrhage , know arteriovenous malformation aneurysm , head trauma , evidence active bleeding ; Subjects within 48 hour randomization use antiFactor IIa agent dabigatran antiFXa agent rivaroxaban , apixaban , edoxaban ; Subjects within 21 day prior randomization gastrointestinal genitourinary bleeding ; Subjects within 14 day prior randomization major surgery lumbar puncture ( epidural steroid injection ) ; Subjects diagnose active liver disease elevation liver enzymes/bilirubin .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Venous thromboembolism</keyword>
	<keyword>VTE</keyword>
	<keyword>Pulmonary embolism</keyword>
	<keyword>PE</keyword>
	<keyword>Acute Submassive Pulmonary Embolism</keyword>
</DOC>